BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22098272)

  • 1. Rifaximin improves thrombocytopenia in patients with alcoholic cirrhosis in association with reduction of endotoxaemia.
    Kalambokis GN; Mouzaki A; Rodi M; Tsianos EV
    Liver Int; 2012 Mar; 32(3):467-75. PubMed ID: 22098272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endotoxaemia in the pathogenesis of cytopenias in liver cirrhosis. Could oral antibiotics raise blood counts?
    Kalambokis G; Tsianos EV
    Med Hypotheses; 2011 Jan; 76(1):105-9. PubMed ID: 20832949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance.
    Fujimoto M; Uemura M; Nakatani Y; Tsujita S; Hoppo K; Tamagawa T; Kitano H; Kikukawa M; Ann T; Ishii Y; Kojima H; Sakurai S; Tanaka R; Namisaki T; Noguchi R; Higashino T; Kikuchi E; Nishimura K; Takaya A; Fukui H
    Alcohol Clin Exp Res; 2000 Apr; 24(4 Suppl):48S-54S. PubMed ID: 10803780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites.
    Kalambokis GN; Mouzaki A; Rodi M; Pappas K; Fotopoulos A; Xourgia X; Tsianos EV
    Clin Gastroenterol Hepatol; 2012 Jul; 10(7):815-8. PubMed ID: 22391344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease.
    Gangarapu V; Ince AT; Baysal B; Kayar Y; Kılıç U; Gök Ö; Uysal Ö; Şenturk H
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):840-5. PubMed ID: 26043290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
    Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
    World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy.
    Jain L; Sharma BC; Srivastava S; Puri SK; Sharma P; Sarin S
    J Gastroenterol Hepatol; 2013 Jul; 28(7):1187-93. PubMed ID: 23425082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients.
    Mostafa T; Badra G; Abdallah M
    Turk J Gastroenterol; 2015 Mar; 26(2):163-9. PubMed ID: 25835116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The relationship among the counts of platelet, thrombopoietin and spleen index in patients with liver cirrhosis].
    Li Q; Sun GZ; Wang BE; Jia JD; Ma H; Wei YX; Cong YL; Shen J
    Zhonghua Gan Zang Bing Za Zhi; 2004 Apr; 12(4):210-2. PubMed ID: 15099468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis.
    Vlachogiannakos J; Viazis N; Vasianopoulou P; Vafiadis I; Karamanolis DG; Ladas SD
    J Gastroenterol Hepatol; 2013 Mar; 28(3):450-5. PubMed ID: 23216382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma interleukin-6 levels in patients with cirrhosis. Relationship to endotoxemia, tumor necrosis factor-alpha, and hyperdynamic circulation.
    Lee FY; Lu RH; Tsai YT; Lin HC; Hou MC; Li CP; Liao TM; Lin LF; Wang SS; Lee SD
    Scand J Gastroenterol; 1996 May; 31(5):500-5. PubMed ID: 8734349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does low-dose rifaximin ameliorate endotoxemia in patients with liver cirrhosis: a prospective study.
    Zeng X; Tang XJ; Sheng X; Ni W; Xin HG; Chen WZ; Jiang CF; Lin Y; Shi J; Shi B; Chen YX; Yuan ZL; Xie WF
    J Dig Dis; 2015 Nov; 16(11):665-74. PubMed ID: 26474237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis.
    Chen TA; Tsao YC; Chen A; Lo GH; Lin CK; Yu HC; Cheng LC; Hsu PI; Tsai WL
    Scand J Gastroenterol; 2009; 44(5):619-25. PubMed ID: 19191184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees.
    Kuipers B; van der Poll T; Levi M; van Deventer SJ; ten Cate H; Imai Y; Hack CE; ten Cate JW
    J Immunol; 1994 Mar; 152(5):2438-46. PubMed ID: 8133055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombocytopenia associated with chronic liver disease: effects of rifaximin on platelet count.
    Kalambokis G; Tsianos EV
    Am J Gastroenterol; 2010 Dec; 105(12):2705-7. PubMed ID: 21131941
    [No Abstract]   [Full Text] [Related]  

  • 16. Neonatal gut barrier and multiple organ failure: role of endotoxin and proinflammatory cytokines in sepsis and necrotizing enterocolitis.
    Sharma R; Tepas JJ; Hudak ML; Mollitt DL; Wludyka PS; Teng RJ; Premachandra BR
    J Pediatr Surg; 2007 Mar; 42(3):454-61. PubMed ID: 17336180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombopoietin or interleukin-6 has no effect on thrombocytopenia of cirrhosis.
    Ozer B; Serin E; Sezgin N; Cosar A; Güclü M; Gur G; Yilmaz U; Boyacioglu S
    Hepatogastroenterology; 2007 Jun; 54(76):1187-91. PubMed ID: 17629067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-necrosis-factor and interleukin-6 response of peripheral blood monocytes to low concentrations of lipopolysaccharide in patients with alcoholic liver disease.
    Schäfer C; Schips I; Landig J; Bode JC; Bode C
    Z Gastroenterol; 1995 Sep; 33(9):503-8. PubMed ID: 8525652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis.
    Vlachogiannakos J; Saveriadis AS; Viazis N; Theodoropoulos I; Foudoulis K; Manolakopoulos S; Raptis S; Karamanolis DG
    Aliment Pharmacol Ther; 2009 May; 29(9):992-9. PubMed ID: 19210289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small bowel bacterial overgrowth and endotoxemia in cirrhosis.
    Wang J; Chen M; Sun G; Et Al
    Zhonghua Nei Ke Za Zhi; 2002 Jul; 41(7):459-61. PubMed ID: 12189115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.